CANCELLED: Accelerating Precision Cancer Medicine through Clinical Computational Oncology

Add event to my Google calendar Add event to my Google calendar Share this event on facebook E-mail this event
Wednesday, February 08, 2017 4:00pm - 5:00pm
Watson CIT - SWIG Boardroom (CIT241)

 

DUE TO ILLNESS THIS HAS BEEN CANCELLED. Further details will follow regarding rescheduling Dr. Van Allen.

 

Dr. Eliezer Van Allen

Assistant Professor of Medicine, Harvard Medical School
Clinician, Dana Farber /Partners Cancer Care
Associate Member, Broad Institute

Accelerating Precision Cancer Medicine through Clinical Computational Oncology

 The increasing ability to generate vast data from a cancer patient’s tumor and germline DNA at the point-of-care has required the development of a scientific discipline to harness this information avalanche for clinical and translational purposes: clinical computational oncology. This field, defined by the development and application of algorithms that analyze and interpret multi-omic data directly from patients to tackle scientific questions grounded in clinical care, has catalyzed new discoveries that directly impact precision cancer medicine strategies in many ways. This includes 1) prospective identification of patient-specific genomic features linked to therapeutic actions to guide individualized care, 2) definition of genomic mediators of response to existing and emerging cancer therapies, and 3) discovery of clinical tumor evolution mechanisms in multiple therapeutic resistance scenarios. In this presentation, I will explore the development of clinical computational oncology through specific examples in melanoma and prostate cancer, and demonstrate how this field has accelerated translational and clinical oncology discovery and enabled bioinformatics methodologies driven by clinically grounded investigators to be applied at the point of care. Future efforts that expand this science across cancers and populations will inform their utility for precision cancer medicine.

Hosted by The Ramachandran Group